2019 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ : 2019-12-06±³À°ÀÏÀÚ : 2019-12-06
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú È£ÅÚ ºñ½ºÅ¸È¦B2F
±³À°ÁÖÁ¦ :
2019 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520
À̸ÞÀÏ :
retina@retina.or.kr ±³À°Á¾·ù : ¾È°ú
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 53ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í »çÀüµî·Ï: Àü°ø/ÀüÀÓÀÇ 6¸¸¿ø Àü¹®ÀÇ 8¸¸¿ø ÇöÀåµî·Ï: Àü°ø/ÀüÀÓÀÇ 8¸¸¿ø Àü¹®ÀÇ 10¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-06 09:00~09:08 Injectable Drug-Loaded Core/Shell Rod for Temporally Controlled Delivery of Bevacizumab and Dexamethasone: A Prolonged and Synergetic Therapy for Retinal Vascular Diseases ¿øÀ翬(°¡Å縯´ë)
±³À°½Ã°£ 12-06 09:08~09:16 Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynam ¾çÇö½Â(½Å¼¼°è¾È°ú)
±³À°½Ã°£ 12-06 09:16~09:24 Çѱ¹Àο¡¼ Ȳ¹ÝºÎ ¸ð¼¼Ç÷°üÈ®ÀåÁõ 2ÇüÀÇ ÀÓ»ó¾ç»ó ºÐ¼®: ´Ù±â°ü °øµ¿¿¬±¸ À̱âȲ(¾ÆÁÖ´ë)
±³À°½Ã°£ 12-06 09:24~09:32 Inhibition of mTOR via an AAV-delivered shRNA tested in a rat OIR model as a potential anti-angiogenic gene therapy ÀÌÁÖ¿ë(¿ï»ê´ë)
±³À°½Ã°£ 12-06 09:32~09:40 Descriptive Epidemiology for Common Retinal Diseases from the National Claims Database ¹Ú»óÁØ(¼¿ï´ë)
±³À°½Ã°£ 12-06 10:00~10:15 Let's dig deep into eye: from classification to image generation using deep learning ¼Û¼öÁ¤(¼º±Õ°ü´ë)
±³À°½Ã°£ 12-06 10:15~10:45 AI in Ophthalmology Daniel Ting Shu Wei(Singapore national eye center)
±³À°½Ã°£ 12-06 10:45~11:00 Artificial intelligence ±ÇÁظí(¼¼Á¾º´¿ø)
±³À°½Ã°£ 12-06 11:20~11:35 What can we predict with OCTA for inrtravitreal injection ±è¼º¿ì(°í·Á´ë)
±³À°½Ã°£ 12-06 11:35~11:50 Myopic Tractional Maculopathy - Surgical consideration °íÇüÁØ(¿¬¼¼´ë)
±³À°½Ã°£ 12-06 11:50~12:20 Ultra wide-field OCT of vitreoretinal observation Kyoko Ohno-matsui(Tokyo Univ.)
±³À°½Ã°£ 12-06 12:30~13:00 Lucentis Optimal treatment option for DME patient À̱âȲ(¾ÆÁÖ´ë)
±³À°½Ã°£ 12-06 13:00~13:30 Why are we insensitive to safety issue of anti-VEGF? ±èÀ¯Ã¶(°è¸í´ë)
±³À°½Ã°£ 12-06 14:00~14:15 ROP vitrectomy Shunji KUSAKA(Kimdai Univ.)
±³À°½Ã°£ 12-06 14:15~14:30 Various phenotypes and genetics of FEVR ±è»óÁø(¼º±Õ°ü´ë)
±³À°½Ã°£ 12-06 14:30~14:45 Surgical Management of FEVR Shunji KUSAKA(Kindai Univ.)
±³À°½Ã°£ 12-06 14:45~15:00 Pediatric retinal detachment and stickler syndrome ¿ì¼¼ÁØ(¼¿ï´ë)
±³À°½Ã°£ 12-06 15:20~15:35 Next Generation Analysis of Patient-derived Membranes in Proliferative Vitreoretinopathy Leo Kim(Harvard Univ.)
±³À°½Ã°£ 12-06 15:35~16:05 Dual Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in nAMD: Results of Phase 2 Trials Nicholas Fung(Hong Kong Univ.)
±³À°½Ã°£ 12-06 16:05~16:20 Examining Brolucizumab Data À¯½Â¿µ(°æÈñ´ë)
±³À°½Ã°£ 12-06 16:20~16:35 Anti-VEGF biosimilar for neovascular AMD À¯Çü°ï(¼¿ï´ë)
±³À°½Ã°£ 12-06 16:35~16:45 Àΰø¸Á¸·°³¹ßÀÇ ¾î·Á¿ò°ú ¹Ì·¡ ¼Á¾¸ð(¼¿ï´ë)
±³À°½Ã°£ 12-06 17:00~17:08 Association of age-related macular degeneration with Alzheimer¡¯s disease and Parkinson¡¯s disease Áöµ¿Çö(°¡Å縯´ë)
±³À°½Ã°£ 12-06 17:08~17:16 Differential proteins in the aqueous humor from patients with drusen and reticular pseudodrusen Á¤Çý¿ø(°Ç±¹´ë)
±³À°½Ã°£ 12-06 17:16~17:24 Changes in OCT angiography and disease activity in type 3 neovascularization after anti-vascular endothelial growth factor treatment Á¶ÇÑÁÖ(±è¾È°úº´¿ø)
±³À°½Ã°£ 12-06 17:24~17:32 Choroid and choriocapillaris in non-exudative age related macular degeneration À±Ã¶¹Î(°í·Á´ë)
±³À°½Ã°£ 12-06 17:32~17:40 Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment ±èÀçÈÖ(±è¾È°ú)
±³À°½Ã°£ 12-06 17:40~17:48 Depression and anxiety of patients with neovascular age-related macular degeneration according to related factors. ±èÁø¿µ(Á¦ÁÖ´ë)
±³À°½Ã°£ 12-06 18:00~18:30 The Role of Steroids in the Management of Diabetic Macular Edema ±èÁ¤¿(Ãæ³²´ë)
±³À°½Ã°£ 12-06 18:30~19:00 Personalized management of DME with early Ozurdex treatment ÀÌÁöÀº(ºÎ»ê´ë)